Comparison of benzoate- and dodecaborate-based linkers for attachment of radioiodine to HER2-targeting Affibody ligand

International Journal of Molecular Medicine

Volumn 19, Issue 3, 2007, Pages 485-493

  Tran, Thuy ^a   Orlova, Anna ^a,b   Sivaev, Igor ^c   Sandström, Mattias ^d   Tolmachev, Vladimir ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c A N NESMEYANOV INSTITUTE OF ORGANOELEMENT COMPOUNDS   (Russian Federation)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HER2; Herceptin; Radionuclide molecular imaging

Indexed keywords

BENZOIC ACID DERIVATIVE; BORON DERIVATIVE; DODECABORATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIGAND; RADIOACTIVE IODINE; UNCLASSIFIED DRUG;

AFFINITY LABELING; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOAVAILABILITY; CHEMISTRY; COMPARATIVE STUDY; DRUG SCREENING; HUMAN; METABOLISM; MOUSE; SCINTISCANNING; TUMOR CELL LINE; WHOLE BODY IMAGING;

AFFINITY LABELS; ANIMALS; BENZOATES; BIOLOGICAL AVAILABILITY; BORON COMPOUNDS; CELL LINE, TUMOR; HUMANS; IODINE RADIOISOTOPES; LIGANDS; MICE; MICE, INBRED BALB C; RADIONUCLIDE IMAGING; RECEPTOR, ERBB-2; WHOLE BODY IMAGING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33947516890     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.19.3.485     Document Type: Article

References (48)

1. Natali PG, Nicotra MR, Bigotti A, Venturo I, Slamon DJ, Fendly BM and Ullrich A: Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer 45: 457-461, 1990.
2. Press MF, Cordon-Cardo C and Slamon DJ: Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962, 1990.
3. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
4. Carter P, Presta L, Gorman CM, Ridway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
5. Ocana A, Rodriguez CA and Cruz JJ: Integrating trastuzumab in the treatment of breast cancer. Current status and future trends. Clin Transl Oncol 7: 99-100, 2005.
6. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG and Somerfield MR; American Society of Clinical Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1865-1878, 2001.
7. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G and Stieber P: Tumor markers in breast cancer - European Group on tumor marker recommendations. Tumour Biol 26: 281-293, 2005. (Pubitemid 41619458)
8. Heppeler A, Froidevaux S, Eberle AN and Maecke HR: Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7: 971-994, 2000.
9. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M and Yarden Y: The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96: 4995-5000, 1999.
10. Behr TM, Behe M and Wormann B: Trastuzumab and breast cancer. N Engl J Med 345: 995-996, 2001.
11. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N and Larson SM: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22: 701-706, 2004.
12. 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol 32: 51-58, 2005.
13. Gonzalez Trotter DE, Manjeshwar RM, Doss M, Shaller C, Robinson MK, Tandon R, Adams GP and Adler LP: Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. J Nucl Med 45: 1237-1244, 2004.
14. Olafsen T, Tan GJ, Cheung CW, Yazaki PJ, Park JM, Shively JE, Williams LE, Raubitschek AA, Press MF and Wu AM: Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17: 315-323, 2004.
15. Nord K, Gunneriusson E, Ringdahl J, Ståhl S, Uhlén M, and Nygren P-Å: Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15: 772-777, 1997.
16. Wikman M, Steffen A-C, Gunneriusson E, Tolmachev V, Adams GP, Carlsson J and Ståhl S: Selection and characterisation of HER2/neu-binding affibody ligands. Protein Eng Des Sel 17: 455-462, 2004.
17. Orlova A, Magnusson M, Eriksson T, Nilsson M, Larsson B, Höiden-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S and Nilsson F: Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 66: 4339-4348, 2006.
18. HER2:342, an Affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47: 846-853, 2006.
19. Oriuchi N, Higuchi T, Hanaoka H, Iida Y and Endo K: Current status of cancer therapy with radiolabelled monoclonal antibody. Ann Nucl Med 19: 355-365, 2005.
20. Leonard JP, Siegel JA and Goldsmith SJ: Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest 21: 241-252, 2003.
21. Riccabona G and Decristoforo C: Peptide targeted imaging of cancer. Cancer Biother Radiopharm 18: 675-687, 2003.
22. Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, Gonzalez Trotter DE and Adams GP: Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labelled anti-HER2 diabody. Cancer Res 15: 1471-1478, 2005.
23. Tolmachev V, Orlova A and Lundqvist H: Approaches to improvement of cellular retention of radiohalogen labels delivered by internalizing tumor targeting proteins and peptides. Curr Med Chem 10: 2447-2460, 2003.
24. 76Br]Bromo-DABI). Nucl Med Biol 31: 205-211, 2004.
25. 125I]Iodo-DABI). Anticancer Res 26: 1217-1224, 2006.
26. Persson M, Sivaev I, Winberg KJ, Malmström PU and Tolmachev V: In vitro evaluation of two polyhedral boron anion derivatives as linkers for attachment of radioiodine to the anti-HER2 monoclonal antibody trastuzumab. In: Antibody Mediated Radionuclide Targeting of HER-2 for Cancer Diagnostics and Therapy: Preclinical Studies. Persson M (ed). Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206, 140, 2006.
27. Koziorowski J, Henssen C and Weinreich R: A new convenient route to radioiodinated N-succinimidyl 3- and 4-iodobenzoate, two reagents for iodination of proteins. Appl Radiat Isot 49: 955-959, 1998.
28. -: a new route to water soluble agents for BNCT. Inorg Chem 38: 5887-5893, 1999.
29. Sundberg AL, Blomquist E, Carlsson J, Steffen AC and Gedda L: Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran. Nucl Med Biol 30: 303-315, 2003.
30. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C and Hadary A: Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 93: 552-556, 2005.
31. Weissleder R: Molecular imaging in cancer. Science 312: 1168-1171, 2006.
32. 111In labelled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl Med Biol 27: 827-835, 2000.
33. Behr TM, Gotthardt M, Barth A and Behe M: Imaging tumors with peptide-based radioligands. Q J Nucl Med 45: 189-200, 2001.
34. Reist CJ, Archer GE, Wikstrand CJ, Bigner DD and Zalutsky MR: Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labelling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res 57: 1510-1515, 1997.
35. Vaidyanathan G, Affleck DJ, Bigner DD and Zalutsky MR: Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labelled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate. Nucl Med Biol 29: 1-11, 2002.
36. Foulon CF, Welsh PC, Bigner DD and Zalutsky MR: Positively charged templates for labelling internalizing antibodies: comparison of N-succinimidyl 5-iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR. Nucl Med Biol 28: 769-777, 2001.
37. Shankar S, Vaidyanathan G, Affleck DJ, Peixoto K, Bigner DD and Zalutsky MR: Evaluation of an internalizing monoclonal antibody labelled using N-succinimidyl 3-[131I]iodo-4-phosphonomethylbenzoate ([131I]SIPMB), a negatively charged substituent bearing acylation agent. Nucl Med Biol 31: 909-919, 2004.
38. Stein R, Govindan SV, Mattes MJ, Shih LB, Griffiths GL, Hansen HJ and Goldenberg DM: Targeting human cancer xenografts with monoclonal antibodies labelled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides. Clin Cancer Res 5 (suppl 10): 3079-3087, 1999.
39. Govindan SV, Griffiths GL, Stein R, Andrews P, Sharkey RM, Hansen HJ, Horak ID and Goldenberg DM: Clinical-scale radiolabelling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy. J Nucl Med 46: 153-159, 2005.
40. Tolmachev V and Sjöberg S: Polyhedral boron compounds as potential linkers for attachment of radiohalogens to targeting proteins and peptides. Collect Czech Chem Commun 67: 913-935, 2003.
41. Wilbur DS, Hamlin DK, Srivastava RR and Chyan MK: Synthesis, radioiodination, and biodistribution of some nido- and closo-monocarbon carborane derivatives. Nucl Med Biol 31: 523-530, 2004.
42. Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Risler R, Pathare PM, Quinn J, Vessella RL, Foulon C, Zalutsky M, Wedge TJ and Hawthorne MF: Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds. Bioconjug Chem 15: 203-223, 2004.
43. 111In-DTPA-octreotide. J Nucl Med 46: 1696-1700, 2005.
44. Nestor M, Persson M, Cheng J, Tolmachev V, van Dongen G, Anniko M and Kairemo K: Biodistribution of the chimeric monoclonal antibody U36 radioiodinated with a closododecaborate-containing linker. Comparison with other radioiodination methods. Bioconjug Chem 14: 805-810, 2003.
45. Tolmachev V, Koziorowski J, Sivaev I, Lundqvist H, Carlsson J, Orlova A, Gedda L, Olsson P, Sjoberg S and Sundin A: Closododecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution. Bioconjug Chem 10: 338-345, 1999.
46. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS, Stafford WF III, Bookman MA, Fand I, Houston LL and Weiner LM: Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53: 4026-4034, 1993.
47. Tai MS, McCartney JE, Adams GP, Jin D, Hudziak RM, Oppermann H, Laminet AA, Bookman MA, Wolf EJ and Liu S: Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res 55: 5983s-5989s, 1995.
48. Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM and Marks JD: Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 77: 1405-1412, 1998.